Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €22.60 EUR
Change Today +0.28 / 1.25%
Volume 372.8K
QIA On Other Exchanges
As of 2:28 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QIA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €24.15
52 Week Low
10/16/14 - €16.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QIAGEN N.V. (QIA)

qiagen n.v. (QIA) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QIA) Details

QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets. The company also offers ingenuity variant analysis, a cloud-based platform to evaluate data generated by NGS technologies; CLC cancer research workbench, a cancer-focused informatics solution; and GeneGlobe, a Web-based portal that enables researchers to search and select from pre-designed and custom PCR assay kits and NGS assay panels. In addition, it provides co-development, technology licenses and patent sales, and custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production. Further, the company offers instrumentation systems for laboratories to perform nucleic acid sample preparation, assay setup, target detection, and interpretation of genomic information. Its automation platforms include QIAsymphony, a modular system; EZ1 Advanced XL for automated nucleic acid purification; QIAcube, a sample processing instrument; QIAcube HT for automated nucleic acid purification; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAgility, a compact benchtop instrument; QIAxcel for nucleic acid separation; and ESEQuant Tube Scanners. The company serves molecular diagnostics, applied testing, pharma, and academia customers. It has collaboration agreement with Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Exosome Diagnostics Inc., and Novartis AG. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,300 Employees
Last Reported Date: 05/7/15
Founded in 1986

qiagen n.v. (QIA) Top Compensated Officers

Chief Executive Officer and Managing Director
Total Annual Compensation: $1.9M
Chief Financial Officer and Managing Director
Total Annual Compensation: $811.0K
Compensation as of Fiscal Year 2014.

qiagen n.v. (QIA) Key Developments

Qiagen Forms Joint Venture with Biotype Diagnostics

QIAGEN N.V., has formed a joint venture with Biotype Diagnostic GmbH. The JV will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN's proprietary ModaPlex platform. QIAGEN will contribute technology and access to its global commercialization engine to the JV, while Biotype Diagnostics will contribute know-how, assay development resources, and its scientific network. QIAGEN will have worldwide distribution rights for the assays, while Biotype Diagnostics will have co-distribution rights for Germany, Austria and Switzerland.

Qiagen NV - Shareholder/Analyst Call

Annual General Meeting of Shareholders

Hitachi High-Technologies Corporation and Qiagen NV Enters into Long-Term Strategic Collaboration for Molecular Testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing. Under terms of the agreement, both companies will bring their unique strengths to the collaboration: Hitachi High-Technologies is recognized as a leader in industrialized instrument development and manufacturing technologies, especially for life sciences and in-vitro diagnostics, while QIAGEN brings its leadership in molecular sample to Insight solutions for use in both the life sciences and clinical diagnostics. Initial projects for the collaboration involve developing new automation systems based on PCR (polymerase chain reaction) and NGS (next-generation sequencing) technologies. Both parties agreed that the collaboration could be expanded in the future to involve co-commercialization of products in specific geographic markets. Further terms of the collaboration are confidential.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €22.60 EUR +0.28

QIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $148.86 USD +0.30
BioMerieux €95.48 EUR -0.52
Cepheid $58.40 USD -0.33
Myriad Genetics Inc $34.85 USD +0.88
PerkinElmer Inc $52.18 USD -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation QIA Industry Range
Price/Earnings 52.4x
Price/Sales 4.3x
Price/Book 2.3x
Price/Cash Flow 39.3x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at